142 results about "Polymyxin B" patented technology

Novel protected cyclopeptide intermediates are prepared from polymyxin B are used to synthesize new peptide antibiotics. Intermediates are readily derivatized and deprotected to provide new families of antibiotics, which have potent anti-bacterial activity against gram-negative bacteria; but also are useful and potent against gram-positive bacteria.

An endotoxin adsorbent used for blood perfusion is prepared from agat through adding the aqueous solution to the liquid mixture of toluene and CCl4 to obtain spherical agar, activating by epoxy chloropropane under alkaline condition, reacting on diamine and then on glutaraldehyde to obtain high-strength agar beads used as the carrier of adsorbent, reacting on the amino contained ligand (polymyxin B), and reducing by NaBH4. Its advantages are high compatibility to blood and high effect on absorbing endotoxin from blood.

The invention relates to an endotoxin adsorbent, which in detail relates to a method of preparing endotoxin adsorbent for blood perfusion. The method employs spherical agarose gel with good biocompatibility as base material, employs epichlorohydrin, hexamethylene diamine, 1, 1'-carbonyldiimidazole as activating agent, and bonds polymyxin B for endotoxin removal. The invention is characterized in that it overcomes the toxicity of cyanogen bromide and instability of aglycone, improves the safty and reliability of operation, reducesnon-specific adsorption through bonding polymyxin B with 1, 1'-carbonyldiimidazole, and improves biocompatibility of adsorbent and suits for treating endotoxemia. The invention is also characterized by simple experimental procedure and high clearance for endotoxin.

The invention relates to the fields of analytical chemistry and food safety, particular to a method for detecting the residual quantity of multiple polypeptide veterinary drugs in animal-derived foods. The method comprises the following steps of: processing a sample with a TCA(trichloroacetic acid) and acetonitrile system for depositing proteins; extracting with a carbinol and 0.1% formic acid aqueous solution system; purifying with a Oasis HLB solid phase extraction column; performing gradient elution with an Eclipse XDB-C18 analytical column in the presence of an acetonitrile and 0.1% formic acid aqueous solution used as a mobile phase; and then performing electrospray and positive ion scanning mode separation for finally detecting four polypeptides. The limits of the four polypeptides, namely colistin, bacitracin A, polymyxin B and virginiamycin M, are 25 micrograms/kilogram, 100 micrograms/kilogram, 250 micrograms/kilogram and 120 micrograms/kilogram respectively; the recovery rates of colistin, bacitracin A, polymyxin B and virginiamycin M are 74.9-88.1%, 76.2-89.0%, 76.6-81.2% and 77.3-86.9% respectively; and the coefficients of variation (CV%) of colistin, bacitracin A, polymyxin B and virginiamycin M are 5.7-15.1%, 7.2-15.7%, 6.0-8.0% and 9.5-18.6% respectively. The detection limit, the recovery rate, the accuracy and other technical indexes all meet related detection requirements at home and aboard.

The invention discloses a preparing method of high-purity polymyxin B. The preparing method comprises the steps of preparation of column-loading solution; injecting the column-loading solution into a high performance liquid chromatography preparative column, wherein sodium sulfate - phosphate buffer / organic solvent is used as mobile phase, collecting target components, removing impurities, especially B1 - 1 and B3, and determining collected solution by means of high performance liquid chromatography (HPLC), wherein chromatographic purity of the target components B1 or B2 or mixture of the B1 and the B2 is more than 99.5%; and purification, wherein vacuum concentration is carried out on the collected target components so that the organic solvent is removed, organic solvent desalination concentration is carried out on balance phase, concentrated solution is spray-dried or freeze-dried to produce the polymyxin B with purity of more than 99.5%. The preparing method of the high-purity polymyxin B has the advantages of being high in purity, high in yield, simple in process, and capable of injecting sample solution continuously. Quality of products is far better than the medical standard regulated by the European Pharmacopoeia (EP) and the United States Pharmacopeia (USP). One-time investment of equipment is slightly high, while operation cost is not high, and therefore the preparing method of the high-purity polymyxin B is suitable for industrial production.

A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.

There is described a composition comprising a therapeutically active imidazole, and derivatives thereof, and an agent active on a bacterial cell surface selected from the group consisting of one or more of colistin, nisin, D-cycloserine, fosfomycin, fosfomycin trometamol, fosfomycin disodium and polymixin B, and derivatives thereof.

The invention provides a method for separately preparing for polymyxin E, which uses foam separation method to extract and separate the polymyxin E from fermentation liquor. The fermentation liquor obtains polymyxin E raw medicine by first treatment, form separating, vacuum evaporation and spray drying.

The invention provides novel polypeptin having potential value of biological control and medical applications, and a preparation method and application thereof. The structure of the polypeptin is shown as a formula (I). The invention has the advantages of providing the polypeptin which has the toxicity lower than that of polymyxin B and has the potential value of biological control and medical applications, and the preparation method and the application thereof. In vitro experiments show that the compound has the obvious effect of inhibiting all the tested gram-positive bacterium, gram-negative bacterium and fungi. Disk-culturing experiments show that the compound has certain effect of preventing and treating various fungal plant diseases and particularly has obvious effects of preventing and treating rice sheath blight.

The invention provides a culture medium used for separating and screening lactic acid bacteria. The formula of the culture medium comprises the following components: relative to the dosage of 1000ml of a solvent, 5.0-15.0g of tryptone, 5.0-15.0g of beef extract, 2.0-10.0g of yeast extract, 1.0-3.0g of diammonium citrate, 15.0-25.0g of glucose, 0.2-2.0 mL of Tween-80, 2.0-8.0g of sodium acetate, 15.0-20.0g of agar, 2.0-30.0g of calcium carbonate, a compound acid-base indicator containing 0.01-0.5g of methyl red and 0.01-0.7g of bromothymol blue, 0.5-5.0g of ascorbic acid, 0.1-0.5g of L-cysteine HCl, and a selective antibiotic composed of 250000-500000 IU of polymyxin B and 0.01-0.05g of nalidixic acid, wherein the pH value of the culture medium is 6.8; and the solvent is composed of a primary solvent and a secondary solvent, the primary solvent is distilled water or aged seawater, and the secondary solvent is saline solution. The culture medium has the characteristics of being high in accuracy, obvious in authentication phenomenon and the like during separation and screening for lactic acid bacteria.

The invention relates to a determination method of polymyxins E residue content in animal source food by superhigh liquid chromatogram-tandom mass spectrometry. The method comprises the following steps: adding an extract in a sample to be measured, fully whirling and extracting, high-speed freezing and centrifuging, then obtaining a sample liquid after filtering and purifying; weighing a polymyxins E standard sample, dissolving by methanol to take it as a storing solution, then further, diluting by methanol to obtain a standard working solution possessing a concentration gradient; detecting the sample by using a superhigh liquid chromatogram-tandom quadrupole liquid chromatography-mass spectrometer; reading out the concentration value of polymyxins E on a standard curve, and calculating the result of polymyxins E of the sample. According to the invention, the determination method of polymyxins E residue in animal source food is rapid and effective, the relative average deviation is less than 10%. Therefore, the method provided in the invention is reliable and easy to enforce for detecting polymyxins E residue in animal source food, which is capable of satisfying the requirments of research and production.

The invention relates to a sterile cultivation method for algae, in particular to a sterile cultivation method for enteromorpha. Firstly, enteromorpha seedlings are washed 2-3 times, and the surfaces of the enteromorpha seedlings are absorbed dry; secondly, three antibiotics including the penicillin G, the neomycin and the polymyxin B are added into a VSE nutrient solution to be prepared into an antibiotic nutrition solution; thirdly, the enteromorpha seedlings are placed in the antibiotic nutrition solution, the cultivation temperature ranges from 18 DEG C to 25 DEG C, the illumination intensity ranges from 130mumol/m<2>*s, the photoperiod is 12L:12D, the enteromorpha seedlings are cultivated in an inflation mode, and the antibiotic nutrition solution is replaced every 3-6 days until the enteromorpha seedlings grow into mature algae. The sterile cultivation is carried out on the enteromorpha collected in the field in a laboratory, the enteromorpha is tested and has no infectious microbe growth, and accordingly the accuracy of the later experiment results of the enteromorpha is greatly improved. The sterile cultivation method is easy to operate, the enteromorpha cultivation system does not need to be changed, raw materials are easy to obtain, price is low, and cost is low.

The invention discloses a method for synthesizing polymyxin B through a fermentation method, which comprises: inoculating bacillus polymyxa ATCC10401 into culture medium to culture and is characterized in that the concentration of the organic nitrogen source which is used in the culture medium is 4%-10%. The highest fermentation unit of the polymyxin B which is synthesized through fermenting by the method can reach 6534.7U/ml.

The invention relates to a method for extracting polymyxin B and E from a fermentation technique culture, which comprises the following steps of: adjusting the pH value of the fermentation technique culture to 10.0 to 14.0 by utilizing an alkaline substance under the temperature of 0 to 25 DEG C and then stirring for 30 min; collecting fungus dregs by utilizing a solid-liquid separation technique to obtain a polymyxin B and E free alkali precipitate; adjusting the pH value of the free alkali precipitate obtained by the solid-liquid separation technique to 1.0 to 6.0 by using an acid substance or solution; after the polymyxin B and E free alkali precipitate is dissolved, carrying out solid-liquid separation to obtain the concentrated solution of polymyxin B and E salts; removing inorganic salts by using a nanofiltration technology; and finally carrying out spray drying to obtain the finished product. The method is characterized by extracting the polymyxin B and E from fermentation liquor in a convenient and high-efficiency mode, solves the problem of high production cost because of high labor strength, long working procedure and low extraction yield in the production process of other extraction methods, and has the advantages of no use of solvents, low cost, environment protection, high yield and low characteristic requirements on the fermentation liquor and equipment.

The invention discloses a legionnella selective separation medium. Dyes such as bromothymol blue and bromocresol purple are added to the basic formulation of the basic medium of legionnella BCYE alphaand legionnella selective antibiotics of glycin, vancocin, polymyxin B and actinone are also added. The added dyes produce pigment in the growth process of legionnella; the shape and the color of a colony are beneficial to identifying and distinguishing a target bacterium of the legionnella; the concentrations of the selective antibiotics are added and regulated, the inhibiting capability to non-legionnella and microbial class is enhanced and the inhibiting performance for the legionnella is reduced, thereby enhancing the positive rate for the separation culture of the legionnella; the detection cost is reduced and the legionnella selective separation medium is economic and practical and is convenient for popularization and application for clinical and health and epidemic prevention departments.

Belonging to the field of animal biomedical engineering, the invention specifically discloses a preparation method of a bacteriophage lyase capable of lysing escherichia coli and salmonella. Through primer design, a lyase gene of bacteriophage ECGD1 is successfully amplified by PCR, and is transferred into an expression system to obtain a recombinant strain. IPTG induction is carried out on the recombinant strain to obtain expression, then the strain is lysed to obtain a soluble recombinant lyase of bacteriophage ECGD1, the recombinant lyase can lyse a plurality of escherichia coli and salmonella, i.e. having a wide lysis spectrum. In addition, the synergistic effect result of the recombinant lyase and polymyxin B shows that the existence of the recombinant lyase lowers the minimum inhibitory concentration of polymyxin B, i.e. the two have a synergistic bacteriostatic effect. Identification on the lysis activity of the recombinant lyase and identification on the wide lysis spectrum thereof reveal that the recombinant lyase of the bacteriophage ECGD1 has potential application value in prevention and control of escherichia coli and salmonella infection.

The invention relates to a selective coloration culture medium for fast culturing and identifying clostridium perfringens. The selective coloration culture medium is characterized in that the preparation of 1000ml of the culture medium requires 12.0g-20.0g of casease hydrolysate, 6.0g-12.0g of yeast extract powder, 0.20g-0.80g of sodium sulfite, 0.005g-0.015g of polymyxin B, 0.05g-0.20g of sulfadiazine, 0.20g-0.80g of ferric citrate, 4-12 units of Y.S.N. and 10.0g-18.0g of agar powder and also requires the final addition of distilled water till the volume of 1000ml is achieved. The selective coloration culture medium has the advantages that the culturing time is obviously reduced when being compared with a conventional method and other bacteria with the same culturing characteristics are inhibited and do not grow so that the effect of fast clostridium perfringens culturing and identification can be realized.

The invention provides a method for producing polymyxin E through fermentation and foam separation coupling. According to the method, polymyxin E is prepared by a circulating reflux device formed by a peristaltic pump through fermentation, film separation and foam separation coupling. During coupling operation, fermentation liquor enters a foam separation tower through a film filter by means of the peristaltic pump, products and a liquid pass through the film while cells are intercepted in a fermentation tank, fermentation continues to be performed, and constancy of bacteria is guaranteed; a foam distributor is mounted at the bottom of the foam separation tower, bubbles are produced through air blowing, foam separation is performed, part of nutrients enter the foam separation tower through the film filter, a remaining liquid produced after foam separation returns to the fermentation tank in a circulating reflux manner, and sufficient utilization of the nutrients is guaranteed; coupling outside a tank body is adopted, operation conditions for fermentation and operation conditions for foam separation are controlled respectively, and the best operation conditions can be met.

The invention discloses an antibacterial drug composition for treating Gram-negative bacterial infections. The composition is prepared from TNP-2092 and a cell membrane penetrant, wherein the cell membrane penetrant is polymyxin B or polymyxin E. According to the antibacterial drug composition for treating Gram-negative bacterial infections, the Gram-negative bacterial infections are treated through the combined use of TNP-2092 and the cell membrane penetrant, the antibacterial activity of the composition is enhanced compared with the use of TNP-2092 or the cell membrane penetrant alone, and the composition has an antibacterial synergistic effect and can be used for treating the Gram-negative bacterial infections, including drug-resistance bacterial infections.

The invention provides a sulfate polymyxin B crystal and a preparation method thereof. The preparation method comprises the following steps: firstly, adsorbing polymyxin B fermented liquid with resin,and adding a sulfate aqueous solution and/or an acid ethanol aqueous solution for desorption to obtain a desorption solution; secondly, adjusting a pH value of the desorption solution obtained in thefirst step to 5.0 to 7.0; and then concentrating until a solid is precipitated to obtain a sulfate polymyxin B saturated solution; and thirdly, in a stirring state, dropwise adding an organic solventinto the sulfate polymyxin B saturated solution obtained in the second step or dropwise adding the sulfate polymyxin B saturated solution obtained in the second step into the organic solvent so as toseparate out the crystal, filtering and drying a filter cake, thus obtaining the sulfate polymyxin B crystal. The solvent used in the preparation method disclosed by the invention is low in cost andeasy to obtain; the preparation method disclosed by the invention is suitable for large-scale industrial production; and the prepared sulfate polymyxin B crystal product has the advantages of higher purity and clarity and low moisture absorption.

The present invention discloses a polymyxin B production fermentation culture medium, a preparation method and uses thereof, wherein the culture medium comprises, by weight, 0.1-1.5 w/w% of an organic nitrogen source, 5.0-15.0 w/w% of whole wheat powder, and 0.3-1.2 w/w% of an inorganic salt.

The invention relates to an endotoxin adsorbent which is composed by taking spherical porous cellulose as a carrier and immobilizing effective amount of polymyxin B as a ligand. The preparation method of the endotoxin adsorbent includes that the spherical porous cellulose is taken as the carrier, the spherical porous cellulose first reacts with sodium periodate and is bonded with the effective amount of polymyxin B, and the endotoxin adsorbent is obtained after reduction by sodium borohydride. The endotoxin adsorbent has the advantages of stable performance, large supported quantity of polymyxin B, good adsorption effect, etc.

The invention discloses application of pithecellobium clypearia extracts to preparation of multi-drug resistant acinetobacter baumannii medicine. The pithecellobium clypearia extracts are prepared through the method includes the steps that pithecellobium clypearia coarse powder is extracted with water or an ethyl alcohol solution, the obtained extraction liquid is extracted with ethyl acetate, and the obtained extracts are target products. The antibacterial function of the pithecellobium clypearia extracts to multi-drug resistant acinetobacter baumannii and the sensitivity enhancing function of the pithecellobium clypearia extracts to similar antibiotics are disclosed for the first time. Tests prove that the pithecellobium clypearia extracts and imipenem or tetracycline or polymyxin B or ceftazidime or levofloxacin take effect together, and the use amount of antibiotics can be reduced by 50-87% compared with the mode that only the pithecellobium clypearia extracts are used. The pithecellobium clypearia extracts can serve as natural multi-drug resistant acinetobacter baumannii medicine or an antibiotic sensitivity-enhancing agent, and is applied to treatment of diseases caused by acinetobacter baumannii. A new means and alternative medicine are provided for solving the drug resistance problem of similar antibiotics.